tbuckley/cabot-search huggingface dataset:
Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper
Authors: Annick Barbaud, Lene Heise Garvey, Alessandra Arcolaci, Knut Brockow, Francesca Mori, Cristobalina Mayorga, Patrizia Bonadonna, Marina Atanaskovic‐Markovic, Luis Moral, Giovanna Zanoni, Mauro Pagani, Angèle Soria, Maja Jošt, Jean‐Christoph Caubet, Abreu Carmo, Al‐Ahmad Mona, Alberto Alvarez‐Perea, Sevim Bavbek, Biagioni Benedetta, M.Beatrice Bilo, Natalia Blanca‐López, Herrera Gádor Bogas, Alessandro Buonomo, Gianfranco Calogiuri, Giulia Carli, Josefina Cernadas, Gabriele Cortellini, Gülfem Celik, Semra Demir, Inmaculada Doña, Adile Berna Dursun, Bernadette Eberlein, Emilia Faria, Bryan Fernandes, Tomaz Garcez, Ignacio Garcia‐Nunez, Radoslaw Gawlik, Asli Gelincik, Eva Gomes, Jimmy H. C. Gooi, Martine Grosber, Theo Gülen, Florence Hacard, Cyrille Hoarau, Christer Janson, Sebastian L. Johnston, Lukas Joerg, Seçil Kepil Özdemir, Ludger Klimek, Mitja Košnik, Marek L. Kowalski, Semanur Kuyucu, Violeta Kvedariene, Jose Julio Laguna, Carla Lombardo, Susana Marinho, Hans Merk, Elisa Meucci, Martine Morisset, Rosa Munoz‐Cano, Francesco Murzilli, Alla Nakonechna, Florin‐Dan Popescu, Grzegorz Porebski, Anna Radice, Frederico S. Regateiro, Heike Röckmann, Antonino Romano, Ravishankar Sargur, Joaquin Sastre, Kathrin Scherer Hofmeier, Lenka Sedláčková, Marta Sobotkova, Ingrid Terreehorst, Regina Treudler, Jolanta Walusiak‐Skorupa, Bettina Wedi, Stefan Wöhrl, Mihael Zidarn, Torsten Zuberbier, Ioana Agache, Maria J. Torres
Journal: Allergy (2022)

Anaphylaxis, which is rare, has been reported after COVID-19 vaccination, but its management is not standardized.Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed.No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine are excipients. The authors propose allergy evaluation of persons with the following histories: 1-anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2-anaphylaxis to oral/topical PEG containing products; 3-recurrent anaphylaxis of unknown cause; 4-suspected or confirmed allergy to any mRNA vaccine; and 5-confirmed allergy to PEG or derivatives. We recommend a prick-to-prick skin test with the left-over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable.These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID-19 vaccines and enable more people with history of allergy to be vaccinated.
RIO DE JANEIRO
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patients With Primary Antibody Deficiency Syndromes Show Attenuated Neutralizing Activity of SARS-CoV-2 Following COVID-19 Vaccination
Authors: Alexa Doss, Rita Chen, Jennifer Monroy, H. James Wedner, Anthony Kulczycki, Tiffany Dy, Zhen Ren, Andrew Kau, Tarisa Mantia, Caitlin O'Shaughnessy, Brandi Nickles, Peggy Kendall, Michael Diamond, Ofer Zimmerman
Journal: Journal of Allergy and Clinical Immunology (2022)
Mast Cells are Locally Activated and Respond to MRGPRX2 Stimulation in Atopic Dermatitis Ex Vivo Skin Biopsies
Authors: Melina Butuci, Zachary Benet, Alan Wong, Julia Schanin, Alan Xu, Amol Kamboj, Brad Youngblood
Journal: Journal of Allergy and Clinical Immunology (2022)
Endoscopic resection of a large tongue-like esophageal mass: a rare case of esophageal striated muscle tumor
Authors: Zhenxiang Wang, Huihui Sun, Yu Zeng, Ying Chen, Jie Xiong, Ye Chen, Shuchang Xu
Journal: Endoscopy (2022)

Corrected by: Correction: Endoscopic resection of a large tongue-like esophageal mass: a rare case of esophageal striated muscle tumorEndoscopy 2022; 54(11): C18-C18DOI: 10.1055/a-1823-3151
Real-time identification of gastric lesions and anatomical landmarks by artificial intelligence during magnetically controlled capsule endoscopy
Authors: Jun Pan, Ji Xia, Bin Jiang, Hang Zhang, Hao Zhang, Zhao-Shen Li, Zhuan Liao
Journal: Endoscopy (2022)

Corrected by: Correction: Real-time identification of gastric lesions and anatomical landmarks by artificial intelligence during magnetically controlled capsule endoscopyEndoscopy 2022; 54(11): C17-C17DOI: 10.1055/a-1761-5217
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
Authors: Milan J. Sonneveld, Shao-Ming Chiu, Jun Yong Park, Sylvia M. Brakenhoff, Apichat Kaewdech, Wai-Kay Seto, Yasuhito Tanaka, Ivana Carey, Margarita Papatheodoridi, Florian van Bömmel, Thomas Berg, Fabien Zoulim, Sang Hoon Ahn, George N. Dalekos, Nicole S. Erler, Christoph Höner zu Siederdissen, Heiner Wedemeyer, Markus Cornberg, Man-Fung Yuen, Kosh Agarwal, Andre Boonstra, Maria Buti, Teerha Piratvisuth, George Papatheodoridis, Chien-Hung Chen, Benjamin Maasoumy
Journal: Journal of Hepatology (2022)

Nucleo(s)tide analogue (NUC) withdrawal may result in HBsAg clearance in a subset of patients. However, predictors of HBsAg loss after NUC withdrawal remain ill-defined.We studied predictors of HBsAg loss in a global cohort of HBeAg-negative patients with undetectable HBV DNA who discontinued long-term NUC therapy. Patients requiring retreatment after treatment cessation were considered non-responders.We enrolled 1,216 patients (991 with genotype data); 98 (8.1%) achieved HBsAg loss. The probability of HBsAg loss was higher in non-Asian patients (adjusted hazard ratio [aHR] 8.26, p <0.001), and in patients with lower HBsAg (aHR 0.243, p <0.001) and HBV core-related antigen (HBcrAg) (aHR 0.718, p = 0.001) levels. Combining HBsAg (<10, 10-100 or >100 IU/ml) and HBcrAg (<2log vs. ≥2 log) levels improved prediction of HBsAg loss, with extremely low rates observed in patients with HBsAg >100 IU/ml with detectable HBcrAg. HBsAg loss rates also varied with HBV genotype; the highest rates were observed for genotypes A and D, and none of the patients with HBV genotype E experienced HBsAg loss (p <0.001 for the overall comparison across genotypes; p <0.001 for genotypes A/D vs. genotypes B/C). HBV genotype C was independently associated with a higher probability of HBsAg loss when compared to genotype B among Asian patients (aHR 2.494; 95% CI 1.490-4.174, p = 0.001).The probability of HBsAg loss after NUC cessation varies according to patient ethnicity, HBV genotype and end-of-treatment viral antigen levels. Patients with low HBsAg (<100 IU/ml) and/or undetectable HBcrAg levels, particularly if non-Asian or infected with HBV genotype C, appear to be the best candidates for treatment withdrawal.A subset of patients may achieve clearance of hepatitis B surface antigen (HBsAg) - so-called functional cure - after withdrawal of nucleo(s)tide analogue therapy. In this multicentre study of 1,216 patients who discontinued antiviral therapy, we identified non-Asian ethnicity, HBV genotype C, and low hepatitis B surface antigen and hepatitis B core-related antigen levels as factors associated with an increased chance of HBsAg loss.
Allergenicity Analysis of Pru p 9 IgE-epitope: The First Peach Aeroallergen
Authors: Laura Martín-Pedraza, Andrea Wangorsch, Natalia Perez Sanchez, Laura Luna, Annette Jamin, Enrique Fernandez-Caldas, Jose Luis Subiza, Jonas Lidholm, Elisa Haroun, María Vazquez de la Torre, Miguel Blanca, Jose Cornejo-Garcia, Stephan Scheurer, Maria Luisa Somoza
Journal: Journal of Allergy and Clinical Immunology (2022)
Trends in Use of Melatonin Supplements Among US Adults, 1999-2018
Authors: Jingen Li, Virend K. Somers, Hao Xu, Francisco Lopez-Jimenez, Naima Covassin
Journal: JAMA (2022)

M. Elisabeth Koopman-Verhoeff, MSc; Michiel A. van den Dries, MSc; Judith J. van Seters, BSc; Maartje P. C. M. Luijk, PhD; Henning Tiemeier, MD, PhD; Annemarie I. Luik, PhD
AMA grams
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The role of the Hippo pathway in autophagy in the heart
Authors: Yasuhiro Maejima, Daniela Zablocki, Jihoon Nah, Junichi Sadoshima
Journal: Cardiovascular Research (2022)

The Hippo pathway, an evolutionarily conserved signalling mechanism, controls organ size and tumourigenesis. Increasing lines of evidence suggest that autophagy, an important mechanism of lysosome-mediated cellular degradation, is regulated by the Hippo pathway, which thereby profoundly affects cell growth and death responses in various cell types. In the heart, Mst1, an upstream component of the Hippo pathway, not only induces apoptosis but also inhibits autophagy through phosphorylation of Beclin 1. YAP/TAZ, transcription factor co-factors and the terminal effectors of the Hippo pathway, affect autophagy through transcriptional activation of TFEB, a master regulator of autophagy and lysosomal biogenesis. The cellular abundance of YAP is negatively regulated by autophagy and suppression of autophagy induces accumulation of YAP, which, in turn, acts as a feedback mechanism to induce autophagosome formation. Thus, the Hippo pathway and autophagy regulate each other, thereby profoundly affecting cardiomyocyte survival and death. This review discusses the interaction between the Hippo pathway and autophagy and its functional significance during stress conditions in the heart and the cardiomyocytes therein.
Haploinsufficiency of PSMD12 Causes Proteasome Dysfunction and Subclinical Autoinflammation
Authors: Kai Yan, Jiahui Zhang, Pui Y. Lee, Panfeng Tao, Jun Wang, Shihao Wang, Qing Zhou, Minyue Dong
Journal: Arthritis & Rheumatology (2022)

Proteasome-associated autoinflammatory syndrome (PRAAS) is caused by mutations affecting components of the proteasome and activation of the type I interferon (IFN) pathway. This study was undertaken to investigate the pathogenic mechanisms of a newly recognized type of PRAAS caused by PSMD12 haploinsufficiency.Whole-exome sequencing was performed in members of a family with skin rash, congenital uveitis, and developmental delay. We performed functional studies to assess proteasome dysfunction and inflammatory signatures in patients, and single-cell RNA sequencing to further explore the spectrum of immune cell activation.A novel truncated variant in PSMD12 (c.865C>T, p.Arg289*) was identified in 2 family members. The impairment of proteasome function was found in peripheral blood mononuclear cells (PBMCs), as well as in PSMD12-knockdown HEK 293T cell lines. Moreover, we defined the inflammatory signatures in patient PBMCs and found elevated IFN signals, especially in monocytes, by single-cell RNA sequencing.These findings indicate that PSMD12 haploinsufficiency causes a set of inflammation signatures in addition to neurodevelopmental disorders. Our work expands the genotype and phenotype spectrum of PRAAS and suggests a bridge between the almost exclusively inflammatory phenotypes in the majority of PRAAS patients and the almost exclusively neurodevelopmental phenotypes in the previously reported Stankiewicz-Isidor syndrome.
Early CPAP versus Surfactant in Extremely Preterm Infants
Authors: Neil N Finer, Waldemar A Carlo, Michele C Walsh, Wade Rich, Marie G Gantz, Abbot R Laptook, Bradley A Yoder, Roger G Faix, Abhik Das, W Kenneth Poole, Edward F Donovan, Nancy S Newman, Namasivayam Ambalavanan, Ivan D Frantz, Susie Buchter, Pablo J Sánchez, Kathleen A Kennedy, Nirupama Laroia, Brenda B Poindexter, C Michael Cotten, Krisa P Van Meurs, Shahnaz Duara, Vivek Narendran, Beena G Sood, T Michael O'Shea, Edward F Bell, Vineet Bhandari, Kristi L Watterberg, Rosemary D Higgins
Journal: New England Journal of Medicine (2010)

There are limited data to inform the choice between early treatment with continuous positive airway pressure (CPAP) and early surfactant treatment as the initial support for extremely-low-birth-weight infants.
Social Determinants of Health and Comorbid Conditions Related to Presentation in the Healthcare Setting Among Patients with Sinonasal Conditions Farhan Salman, Raktima Dasgupta, Kamal M. Eldeirawi, Sharmilee M. Nyenhuis, Victoria S. Lee
Authors: Farhan Salman, Raktima Dasgupta, Kamal Eldeirawi, Sharmilee Nyenhuis, Victoria Lee
Journal: Journal of Allergy and Clinical Immunology (2022)
Text-Book on Mental Diseases.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nanoporous materials for pesticide formulation and delivery in the agricultural sector
Authors: Gurwinder Singh, Kavitha Ramadass, Prasanthi Sooriyakumar, Oshadi Hettithanthri, Meththika Vithange, Nanthi Bolan, Ehsan Tavakkoli, Lukas Van Zwieten, Ajayan Vinu
Journal: Journal of Controlled Release (2022)
Clinical Characteristics, Management and Triggers of Mastocytosis in a Cohort of 39 Patients
Authors: Connor Prosty, Sofianne Gabrielli, Madison Le Gallee, Mahdi Hassan, Audrey Lovett, Barbara Miedzybrodzki, Sharon Baum, Shoshana Greenberger, Shawna Lechner-Rempel, Elena Netchiporouk, Moshe Ben-Shoshan
Journal: Journal of Allergy and Clinical Immunology (2022)
Books in Brief
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer
Authors: Xiao-Shan Wang, Yi-Feng Bai, Vivek Verma, Rui-Lian Yu, Wei Tian, Rui Ao, Ying Deng, Xue-Qiang Zhu, Hao Liu, Hai-Xia Pan, Lan Yang, Han-Song Bai, Xing Luo, Yan Guo, Ming-Xiu Zhou, Yue-Mei Sun, Zi-Can Zhang, Si-Min Li, Xue Cheng, Bang-Xian Tan, Liang-Fu Han, Ying-Yi Liu, Kai Zhang, Fan-Xin Zeng, Lin Jia, Xin-Bao Hao, You-Yu Wang, Gang Feng, Ke Xie, You Lu, Ming Zeng
Journal: JNCI Journal of the National Cancer Institute (2022)

Adding radiotherapy (RT) to systemic therapy improves progression-free survival (PFS) and overall survival (OS) in oligometastatic non-small cell lung cancer (NSCLC). Whether these findings translate to epidermal growth factor receptor (EGFR)-mutated NSCLC remains unknown. The SINDAS trial (NCT02893332) evaluated first-line tyrosine kinase inhibitor (TKI) therapy for EGFR-mutated synchronous oligometastatic NSCLC and randomized to upfront RT vs no RT; we now report the prespecified interim analysis at 68% accrual.Inclusion criteria were biopsy-proven EGFR-mutated adenocarcinoma (per amplification refractory mutation system or next generation sequencing), with synchronous (newly diagnosed, treatment naïve) oligometastatic (≤5 metastases; ≤2 lesions in any one organ) NSCLC without brain metastases. All patients received a first-generation TKI (gefitinib, erlotinib, or icotinib), and randomization was between no RT vs RT (25-40 Gy in 5 fractions depending on tumor size and location) to all metastases and the primary tumor/involved regional lymphatics. The primary endpoint (intention to treat) was PFS. Secondary endpoints included OS and toxicities. All statistical tests were 2-sided.A total of 133 patients (n = 65 TKI only, n = 68 TKI with RT) were enrolled (2016-2019). The median follow-up was 23.6 months. The respective median PFS was 12.5 months vs 20.2 months (P < .001), and the median OS was 17.4 months vs 25.5 months (P < .001) for TKI only vs TKI with RT. Treatment yielded no grade 5 events and a 6% rate of symptomatic grade 3-4 pneumonitis in the TKI with RT arm. Based on the efficacy results of this prespecified interim analysis, the ethics committee recommended premature cessation of this trial.As compared with a first-line TKI alone, addition of upfront local therapy using RT statistically significantly improved PFS and OS for EGFR-mutated NSCLC.
Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial
Authors: Andreas Wollenberg, Lisa Beck, Mette Sondergaard Deleuran, Andrew Blauvelt, Jacob Thyssen, Marjolein de Bruin-Weller, Zhen Chen, Faisal Khokhar, Ainara Rodriguez-Marco, Noah Levit
Journal: Journal of Allergy and Clinical Immunology (2022)
Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management
Authors: Natasha Szuber, Michelle Elliott, Ayalew Tefferi
Journal: American Journal of Hematology (2022)

Chronic neutrophilic leukemia (CNL) is a rare, often aggressive myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis, bone marrow granulocyte hyperplasia, and frequent hepatosplenomegaly. The 2013 seminal discovery of oncogenic driver mutations in colony-stimulating factor 3 receptor (CSF3R) in the majority of patients with CNL not only established its molecular pathogenesis but provided a diagnostic biomarker and rationale for pharmacological targeting.In 2016, the World Health Organization (WHO) recognized activating CSF3R mutations as a central diagnostic feature of CNL. Other criteria include leukocytosis of ≥25 × 109 /L comprising >80% neutrophils with <10% circulating precursors and rare blasts, and absence of dysplasia or monocytosis, while not fulfilling criteria for other MPN.There is currently no standard of care for management of CNL, due in large part to the rarity of disease and dearth of formal clinical trials. Most commonly used therapeutic agents include conventional oral chemotherapy (e.g., hydroxyurea), interferon, and Janus kinase (JAK) inhibitors, while hematopoietic stem cell transplant remains the only potentially curative modality.Increasingly comprehensive genetic profiling in CNL, including new data on clonal evolution, has disclosed a complex genomic landscape with additional mutations and combinations thereof driving disease progression and drug resistance. Although accurate prognostic stratification and therapeutic decision-making remain challenging in CNL, emerging data on molecular biomarkers and the addition of newer agents, such as JAK inhibitors, to the therapeutic arsenal, are paving the way toward greater standardization and improvement of patient care.
TCT-2 Coronary angiographic findings and outcomes in patients with sudden cardiac arrest without ST-elevation myocardial infarction: a SWEDEHEART study
Authors: Axel Wester, Moman Mohammad, Sasha Koul, Pontus Andell, Rebecca Rylance, Josef Dankiewicz, Hans Friberg, Stefan James, Elmir Omerovic, David Erlinge
Journal: Journal of the American College of Cardiology (2017)
IFNγ and GM-CSF control complementary differentiation programs in the monocyte-to-phagocyte transition during neuroinflammation
Authors: Ana Amorim, Donatella De Feo, Ekaterina Friebel, Florian Ingelfinger, Cyrill Dimitri Anderfuhren, Sinduya Krishnarajah, Myrto Andreadou, Christina A. Welsh, Zhaoyuan Liu, Florent Ginhoux, Melanie Greter, Burkhard Becher
Journal: Nature Immunology (2022)
Addition of bacterial filter alters positive airway pressure and non-invasive ventilation performances
Authors: Claudio Rabec, Emeline Fresnel, Yann Rétory, Kaixian Zhu, Karima Joly, Adrien Kerfourn, Benjamin Dudoignon, Alexis Mendoza, Antoine Cuvelier, Jean-François Muir, Boris Melloni, Jean-François Chabot, Jésus Gonzalez-Bermejo, Maxime Patout
Journal: European Respiratory Journal (2022)

<b>The recommendation to add a bacterial filter on home positive pressure devices has significant negative impact on their performances and precludes auto-titrating positive airway pressure to function. These data suggest to not follow such recommendation.</b>https://bit.ly/31YrWyo